Efficacy and safety of AZD6244 (ARRY-142886) as second/third-line treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC)

被引：30

作者：

Tzekova, V.

Cebotaru, C.

Ciuleanu, T. E.

Damjanov, D.

Ganchev, H.

Kanarev, V.

Stella, P. J.

Sanders, N.

Pover, G.

Hainsworth, J. D.

机构：

[1] MHAT Queen Joanna, Sofia, Bulgaria

[2] Oncologcal Inst I Chiricuta, Cluj Napoca, Romania

[3] Natl Oncol Ctr, BU-1157 Sofia, Bulgaria

[4] MHAT St Marina, Varna, Bulgaria

[5] Reg Oncol Dispensary Plovdiv, Plovdiv, Bulgaria

[6] St Joseph Mercy Canc Care Ctr, Ann Arbor, MI USA

[7] AstraZeneca, Loughborough, Leics, England

[8] AstraZeneca, Macclesfield, Cheshire, England

[9] Sarah Cannon Res Inst, Nashville, TN USA

来源：

关键词：

D O I：

10.1200/jco.2008.26.15_suppl.8029

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8029

引用

页数：1